Scinai Immunotherapeutics
SCNI
7 hedge funds and large institutions have $58.4K invested in Scinai Immunotherapeutics in 2025 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
17% more funds holding
Funds holding: 6 → 7 (+1)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
4% less capital invested
Capital invested by funds: $60.9K → $58.4K (-$2.5K)
2.24% less ownership
Funds ownership: 4.81% → 2.57% (-2.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$31.1K |
| 2 |
VF
Virtu Financial
New York
|
+$17.6K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$6.76K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$1.98K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$18.6K |
| 2 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$1.91K |
| 3 |
Morgan Stanley
New York
|
-$213 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $24.6K | +$6.76K | +5,932 | +21% |
|
|
XT
2
XTX Topco
George Town,
Cayman Islands
| $19.4K | +$31.1K | +27,294 | New |
|
|
VF
3
Virtu Financial
New York
| $11K | +$17.6K | +15,409 | New |
|
|
4
RhumbLine Advisers
Boston,
Massachusetts
| $1.33K | -$1.91K | -1,675 | -47% |
|
|
5
UBS Group
Zurich,
Switzerland
| $1.25K | +$1.98K | +1,740 | +21,750% |
|
6
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| $712 | – | – | – |
|
|
7
Morgan Stanley
New York
| $41 | -$213 | -187 | -76% |
|
|
TSS
8
Two Sigma Securities
New York
| – | -$18.6K | -14,696 | Closed |
|
SCNI Hedge Fund Activity: Q4 2025 in Review
7 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q4 2025, worth a combined $58.4K — down 4.1% from $60.9K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new SCNI positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.
The largest buyer was XTX Topco, opening a new position worth an estimated $31.1K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $18.6K sold.
- 7 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q4 2025, up from 6 in Q3 2025.
- Funds reported $58.4K of Scinai Immunotherapeutics stock for Q4 2025, down 4.1% quarter-over-quarter.
- 2 funds opened new Scinai Immunotherapeutics positions in Q4 2025 and 1 closed out, a net change of +1 holder.
- The largest Scinai Immunotherapeutics buyer in Q4 2025 was XTX Topco, an estimated $31.1K added.
- The largest Scinai Immunotherapeutics seller in Q4 2025 was Two Sigma Securities, an estimated $18.6K sold.
Based on aggregated 13F filings for Q4 2025.